Correction to: Imipenem-Relebactam and Meropenem-Vaborbactam: Two Novel Carbapenem-β-Lactamase Inhibitor Combinations

Drugs. 2018 May;78(7):787. doi: 10.1007/s40265-018-0910-x.

George G Zhanel^{1

2}, Courtney K Lawrence³, Heather Adam^{4

5}, Frank Schweizer^{4

6}, Sheryl Zelenitsky³, Michael Zhanel⁴, Philippe R S Lagacé-Wiens^{4

5}, Andrew Walkty^{4

7

5}, Andrew Denisuik⁴, Alyssa Golden⁴, Alfred S Gin^{4

3

8}, Daryl J Hoban^{4

5}, Joseph P Lynch 3rd⁹, James A Karlowsky^{4

5}

¹ Department of Medical Microbiology and Infectious Diseases, Max Rady College of Medicine, University of Manitoba, Winnipeg, Canada. [email protected].
² Department of Medicine, Winnipeg Health Sciences Centre, MS673-820 Sherbrook Street, Winnipeg, Manitoba, R3A 1R9, Canada. [email protected].
³ College of Pharmacy, University of Manitoba, Winnipeg, Canada.
⁴ Department of Medical Microbiology and Infectious Diseases, Max Rady College of Medicine, University of Manitoba, Winnipeg, Canada.
⁵ Diagnostic Services Manitoba, Winnipeg, Canada.
⁶ Department of Chemistry, Faculty of Science, University of Manitoba, Winnipeg, Canada.
⁷ Department of Medicine, Winnipeg Health Sciences Centre, MS673-820 Sherbrook Street, Winnipeg, Manitoba, R3A 1R9, Canada.
⁸ Department of Pharmacy, Winnipeg Health Sciences Centre, Winnipeg, Canada.
⁹ Division of Pulmonary, Critical Care, Allergy and Clinical Immunology, The David Geffen School of Medicine at UCLA, Los Angeles, CA, USA.

Abstract

Section heading 5.2, which currently reads 5.2 Meropenem-Relebactam.